Nouscom just raised $135 million for a single make-or-break trial of its off-the-shelf cancer vaccine. The target: intercepting cancer before it starts in people genetically destined to get it. If it works, it could crack open an entire category of medicine that's been stuck for 16 years.
A Bet on Catching Cancer Early
What if you could vaccinate against cancer the way you vaccinate against the flu? Not cure it after it spreads, but intercept it before it ever becomes a real threat. That's the premise behind Nouscom's lead program, and investors just put $135 million behind the idea.
The Basel, Switzerland-based biotech closed an oversubscribed €120 million (roughly $135 million) Series D round on October 19. The money will fund a single global trial designed to prove that its cancer vaccine works well enough for regulators to approve it. If it succeeds, it could become one of the first therapeutic cancer vaccines to cross the finish line in over a decade.
That's a big "if." But the check writers clearly think it's worth the risk.
Who Wrote the Checks
The round was co-led by M Ventures and Revelation Partners, with new money coming from some heavyweight names: Angelini Industries, the European Investment Bank (through its Aurea co-investment facility), and Neva SGR, part of the Intesa Sanpaolo banking group. Existing backers 5AM Ventures and Andera Partners also came back for more.
That mix matters. You've got specialist biotech investors alongside strategic and institutional capital from Europe's financial establishment. When a European development bank co-invests in a cancer vaccine trial, it signals something beyond garden-variety venture enthusiasm. The round was oversubscribed, meaning more investors wanted in than Nouscom had room for.
The Vaccine: NOUS-209
Nouscom's lead candidate, NOUS-209, works differently from the mRNA cancer vaccines you've probably heard about from Moderna or BioNTech. Instead of custom-building a vaccine for each patient's unique tumor, NOUS-209 is an off-the-shelf product. Think of it like a universal adapter instead of a custom-made cable.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The vaccine uses two specially engineered viral vectors (harmless viruses designed to deliver instructions to your immune system) in a prime-boost approach: one shot primes the immune system, and a follow-up shot boosts the response. Together, they present 209 shared neoantigens to the body. Neoantigens are abnormal proteins found on the surface of cancer cells; they're basically name tags that help your immune system identify the bad guys.
What makes NOUS-209 clever is its target population. The vaccine is designed for people with Lynch syndrome, a hereditary condition that dramatically increases the risk of developing colorectal and other cancers. These patients have a specific genetic defect called mismatch repair deficiency (dMMR), which causes their cells to accumulate predictable mutations. Because those mutations are predictable, the neoantigens they produce are shared across patients, which is why an off-the-shelf vaccine can work here.
It's cancer interception: vaccinating high-risk people to train their immune systems to destroy precancerous cells before they ever become tumors.
Why This Trial Is the Real Test
Nouscom has already shown that NOUS-209 can safely activate the immune system. Earlier clinical data demonstrated that the vaccine triggers CD8+ and CD4+ T-cell responses (the immune cells responsible for hunting and killing threats) in Lynch syndrome carriers. The FDA was impressed enough to grant the program Fast Track designation, which gives the company more frequent meetings with regulators and a potential faster review.
But immune activation alone isn't enough. The FDA has made it clear that therapeutic cancer vaccines need to show real clinical benefit: preventing cancer recurrence, extending survival, or some other meaningful outcome. Biomarker data can support the story, but it can't close the deal by itself.
This pivotal trial needs to answer the question that matters: does vaccinating Lynch syndrome carriers actually prevent cancer from forming? If the answer is yes, it would represent a genuinely new category of medicine.
A Graveyard of Good Ideas
The cancer vaccine field has a long and humbling history. Sipuleucel-T (Provenge) was the first therapeutic cancer vaccine approved by the FDA, back in 2010, followed by talimogene laherparepvec (T-VEC/Imlygic) in 2015 for unresectable melanoma. Since then, no other therapeutic cancer vaccine has crossed the regulatory finish line.
The recent track record hasn't been encouraging either. IO Biotech ran a Phase 3 melanoma trial for its vaccine candidate Cylembio, but the FDA reportedly recommended against submitting it for approval based on those results, advising the company to design a new study instead.
Nouscom is entering a race where the course is littered with DNFs. The competition includes Moderna's mRNA-4157 (currently in Phase 3 for melanoma), OSE Immunotherapeutics' Tedopi (in a pivotal NSCLC trial), and Transgene's TG4050 (in Phase 2). With 277 cancer vaccine clinical trials identified by mid-2025, the field is crowded but still waiting for someone to prove the concept at a regulatory level.
The $135 Million Question
Nouscom has raised capital steadily since its founding in 2015. The company started with a Series A, followed by a $49 million Series B. Its Series C brought in €75.8 million (about $82 million, including an extension). This latest round nearly doubles the previous one, bringing the company's total fundraising well north of $300 million.
All of that money is converging on one trial. One shot to prove that a vaccine can intercept cancer in a genetically defined population. If it works, Nouscom won't just have a product; it will have validated an entirely new way of thinking about cancer prevention. If it doesn't, it joins a very long list of promising ideas that couldn't survive contact with a Phase 3 trial.
The company's founders cut their teeth at Okairos, which GSK acquired in 2013 for its viral vector expertise. That pedigree, combined with a well-defined patient population and a clear regulatory pathway, is what convinced investors to write a nine-figure check.
But the hardest part isn't raising money. It's running the trial and getting the answer right. In cancer vaccines, the science has always been ahead of the proof. Nouscom is betting $135 million that this time will be different.
Clinical & Regulatory
4 min read
Gilead Just Crashed the Biggest Party in Gastroenterology
Gilead's ulcerative colitis pill posted mid-stage results that beat Wall Street expectations, with remission rates nearly four times higher than placebo. The HIV giant just served notice to AbbVie, Takeda, and every other player in the $25 billion IBD market.
